Pharmaceuticals & Healthcare

Biopharma R&D and pipelines, obesity and metabolic drugs, drug pricing and regulation, pharma M&A, telehealth, rare disease, and illicit/counterfeit drug supply.

Lilly's Obesity Franchise: Bullish on Pipeline, Bearish on Legal Risks

Retatrutide's early data and AI efficiencies support a bullish case, but Zepbound's legal challenges inject uncertainty.

By KAPUALabs

/ 19 Jun 2026

Lilly's Obesity Franchise: Bullish on Pipeline, Bearish on Legal Risks

Inside Eli Lilly's Trulicity Rebate Fraud: A Supply Chain Betrayal

Alleged scheme exploited PBM rebates through secondary-market sales, exposing material financial exposure for Lilly's top-selling drug.

By KAPUALabs

/ 19 Jun 2026

Inside Eli Lilly's Trulicity Rebate Fraud: A Supply Chain Betrayal

Tirzepatide: A Definitive Analysis of Efficacy, Safety, and Market Access

Examining the clinical evidence, reimbursement shifts, and strategic outlook for the leading GLP-1 therapy.

By KAPUALabs

/ 18 Jun 2026